Cytori Therapeutics Inc (CYTX) Releases Earnings Results, Reports EPS of $-0.03 EPS

Cytori Therapeutics Inc (CYTX) reported quarterly earnings results on Tuesday, May-10-2016. The company reported $-0.03 EPS for the quarter. Analysts had a consensus estimate of $-0.03. The company posted revenue of $2.90 million in the period, compared to analysts expectations of $2.42 million. The company’s revenue was up 26.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.07 EPS.

Cytori Therapeutics Inc opened for trading at $0.25 and hit $0.26 on the upside on Friday, eventually ending the session at $0.25, with a gain of 5.57% or 0.0132 points. The heightened volatility saw the trading volume jump to 31,28,354 shares. Company has a market cap of $49 M.

In a different news, on Mar 9, 2016, David Rickey (director) purchased 150,000 shares at $0.19 per share price. According to the SEC, on Sep 8, 2015, Tommy G Thompson (director) purchased 25,449 shares at $0.38 per share price. On Sep 3, 2015, Jeremy B. Hayden (General Counsel & VP of BD) purchased 8,200 shares at $0.35 per share price, according to the Form-4 filing with the securities and exchange commission.

Cytori Therapeutics Inc. (Cytori) is a biotechnology company involved in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company is engaged in developing primary product Cytori Cell Therapy for patients with scleroderma hand dysfunction orthopedic disorders cardiovascular disease urinary incontinence and thermal burns combined with radiation injury. The Company commercializes the Celution System under select medical device approvals clearances and registrations to research customers developing new therapeutic applications for Cytori Cell Therapy in Europe Japan and other regions. The Company offers ECCO-50 a cure for knee osteoarthritis which is in ECCO-50 Phase IIA/B of development. It offers ECCI-50 a cure for urinary incontinence which is in Phase II/III of development. The Company is also developing DCCT-10 a cure for cutaneous thermal injury.

Cytori Therapeutics Inc

Leave a Reply

Cytori Therapeutics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Cytori Therapeutics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.